Skip to main content
Premium Trial:

Request an Annual Quote

Cepheid Expects Q3 Revenues In Line with Expectations

NEW YORK (GenomeWeb News) – Cepheid said after the close of the market yesterday that it expects its third-quarter revenues to be roughly $41 million, in line with analysts' consensus estimate of $40.8 million.

The Sunnyvale, Calif.-based firm will report its third-quarter results on Oct. 28, after the close of the market.

Cepheid disclosed its Q3 revenue expectation in a statement announcing that it had hired Nicolaas Arnold to serve as executive vice president of worldwide commercial operations, effective today. Arnold joins Cepheid from Siemens, where he was regional VP for Siemens Healthcare Diagnostics in Northwest Europe with responsibility for molecular diagnostics, central lab, and point-of-care sales.

"We are looking to grow both our domestic and international markets, and this is a timely appointment that further strengthens our sales and marketing capabilities with the objective of establishing the GeneXpert System as the molecular platform of choice," Cepheid CEO John Bishop said in a statement.

Cepheid's shares were up nearly 6 percent at $13.90 in early Wednesday trade on the Nasdaq.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.